The clinical trial, recently detailed in Nature Communications, embraced a profound scientific concept: preconditioning the recipient’s immune system to accept the donor organ as self rather than foreign. This approach centers around the infusion of donor-derived regulatory dendritic cells (DCregs) into the recipient prior to liver transplantation. Derived from monocytes filtered from the donor’s bloodstream, these specialized immune cells modulate the recipient’s immune reactions, promoting a state of tolerance toward the donor liver tissue. Forty-one years after the late Dr. Thomas Starzl’s visionary insights into transplant tolerance, this clinical investigation rekindles hope that immunosuppressant elimination could become the norm for many recipients.

Liver transplantation, unlike many other organ transplants, uniquely benefits from the organ’s inherent regenerative ability. Healthy donors can safely give a portion of their liver to recipients, with both regenerating to functional volumes post-surgery—a biological marvel that enables living-donor liver transplantation (LDLT). UPMC leads the nation in this field, having conducted 89 living-donor liver transplants in 2025 alone. Yet, despite the regenerative power of the liver, post-transplant immunosuppression remains a universal necessity to prevent devastating organ rejection.

Immunosuppressive drugs, while lifesaving, come at an immense physiological price. Their long-term administration is frequently linked to kidney damage, increased vulnerability to infections and malignancies, metabolic derangements like diabetes, and overall diminished quality of life. Recognizing this, the team led by Distinguished Professor Angus Thomson and clinical director Abhinav Humar endeavored to explore the feasibility of instilling immune tolerance through a novel cellular therapy. This approach represents a paradigm shift, moving away from blanket immune suppression toward tailored immune system education.

The trial recruited 13 LDLT patients, who received an infusion of DCregs harvested from their respective donors approximately one week before their scheduled transplant surgery. These regulatory dendritic cells possess the unique ability to induce immune “calmness” by controlling the activation of T cells that are typically responsible for organ rejection. By delivering this cellular therapy ahead of transplantation, the team sought to prime the recipient’s immune system to tolerate the new liver, effectively instructing it to recognize the graft as part of the self.

One year post-transplant, the patients underwent rigorous immunological testing to assess their eligibility for immunosuppressive drug tapering. Of the 13 patients, 8 were deemed fit for gradual withdrawal, with 4 successfully achieving complete cessation of immunosuppressants. Among these, 3 patients have remained off immunosuppressive therapy for over three years without any signs of organ rejection—an unprecedented breakthrough demonstrating the therapy’s long-term potential. This yields a rate of tolerance induction of 37.5% in the withdrawal-eligible cohort, significantly higher than the historical 13% seen in similar patients not receiving the cell infusion.

While these outcomes are undeniably promising, the researchers are cautious to emphasize that the present results are preliminary and exploratory. The trial’s small size and early-phase design preclude definitive conclusions regarding the therapy’s efficacy. Nonetheless, the findings lay an essential foundation for larger, randomized controlled trials designed to compare DCreg infusion head-to-head with the current standard of care, potentially revolutionizing liver transplantation protocols.

The research team also envisions several innovative directions for future exploration. One hypothesis is that administering DCregs post-transplant, rather than exclusively before, may enhance immunological outcomes. They also contemplate utilizing DCregs from deceased donors to expand the therapy’s accessibility. Moreover, investigating alternative immunosuppressive drugs that might synergize more effectively with DCregs could optimize tolerogenic induction. These avenues may substantially improve the proportion of recipients who can safely discontinue immunosuppressants.

This study underscores the deep collaborative ethos driving transplantation science forward. Led by Angus Thomson and Abhinav Humar, the UPMC and University of Pittsburgh teams integrate expertise in surgery, immunology, and clinical translational research. Their commitment honors the legacy of Dr. Thomas Starzl, who three decades ago first championed the dream of immune tolerance in transplantation. Now, the dream edges closer to clinical reality, offering the transplant community, and most importantly patients, new hope for minimizing lifelong drug burdens and enhancing post-surgical health.

The implications of this work extend beyond liver transplantation. The ability to induce durable immune tolerance through tailored cellular therapies may herald a new era for organ transplantation at large, mitigating the need for lifelong immunosuppression across multiple organ systems. Furthermore, this approach could illuminate pathophysiological mechanisms and therapeutic opportunities within numerous immune-mediated diseases where tolerance induction remains a coveted goal.

As the team advances plans for more extensive clinical trials, they invite collaboration with other transplantation centers worldwide to expedite and broaden application of this transformative strategy. The potential to significantly reduce morbidity associated with immunosuppressive drugs through scientifically precise immune system education represents a monumental stride for translational medicine, with ripple effects expected throughout immunology and regenerative science.

In summary, this pioneering phase I/IIa trial demonstrates that donor-derived regulatory dendritic cell infusion prior to living-donor liver transplantation is feasible, safe, and capable of enabling immunosuppressant withdrawal in a meaningful subset of recipients. With continued refinement and validation through rigorous clinical studies, this approach could ultimately redefine the standard of care in organ transplantation, transforming the lives of countless patients grappling with the dual challenges of organ failure and the burdens of immunosuppression.

Subject of Research: Living-donor liver transplantation, immune tolerance induction, regulatory dendritic cell therapy, immunosuppressant withdrawal

Article Title: Donor-derived regulatory dendritic cell infusion and early immunosuppressive drug withdrawal in living-donor liver transplantation: a phase I/IIa trial

News Publication Date: 17-Apr-2026

Web References:
https://doi.org/10.1038/s41467-026-71280-8
https://www.upmc.com/services/transplant/services/living-donor/liver
https://stiresearch.health.pitt.edu/
https://enterprises.upmc.com/

References:
Humar, A., Thomson, A., et al. (2026). Donor-derived regulatory dendritic cell infusion and early immunosuppressive drug withdrawal in living-donor liver transplantation: a phase I/IIa trial. Nature Communications. https://doi.org/10.1038/s41467-026-71280-8

Image Credits: UPMC

Keywords: Organ transplantation, living-donor liver transplant, immune tolerance, immunosuppression withdrawal, regulatory dendritic cells, dendritic cell therapy, translational medicine, immunology, clinical trials, transplant immunology, regenerative medicine, cellular therapy

The realm of blood cancer treatment presents unique challenges, particularly in optimizing hematopoietic stem cell transplantation (HSCT), a cornerstone therapeutic approach for numerous hematological malignancies. The DKMS John Hansen Research Grant is deliberately designed to encourage groundbreaking projects that tackle these challenges head-on. One central emphasis lies in improving transplant immunology, a complex field concerned with the interactions between graft and host immune cells, minimizing graft-versus-host disease (GVHD), and enhancing engraftment kinetics. Research supported by this grant often delves into immune tolerance induction, immune checkpoint modulation, and the nuanced interplay of alloimmune responses — all of which are critical to reducing transplant-related morbidity and mortality.

Stem cell transplantation, though a life-saving intervention, is frequently hindered by complications such as infections, relapse, and organ toxicity. Addressing these complications through innovative research strategies is a key tenet of the DKMS-supported programs. For instance, novel approaches to treat post-transplant complications include the exploration of targeted therapies to mitigate inflammatory cascades or the use of cellular therapies such as regulatory T cells and mesenchymal stromal cells to foster immune regulation. Moreover, scientific efforts are aimed at refining donor selection criteria through sophisticated HLA typing algorithms and next-generation sequencing technologies. These advancements strive to optimize donor-recipient compatibility, enhancing transplant success rates and patient survival.

The organizational infrastructure supporting this research ecosystem is robust and multifaceted. DKMS operates not only the world’s largest stem cell donor registry but also hosts advanced facilities such as the DKMS Stem Cell Bank, Clinical Trials Unit, Collaborative Biobank, and the leading human leukocyte antigen (HLA) typing laboratory globally located in Dresden. The Stem Cell Bank’s unique capability lies in cryopreserving surplus adult stem cells, enabling rapid availability for allogeneic transplants. This technological innovation markedly reduces the waiting time for patients urgently requiring transplantation, setting new clinical standards. Collectively, these resources empower researchers with the tools necessary to conduct high-impact, translational studies bridging laboratory findings and patient care.

International equity in healthcare delivery stands as a critical priority for DKMS. Through strategic global outreach and support programs, the organization is expanding access to life-saving blood stem cell transplants in low- and middle-income countries. Many such regions face significant healthcare infrastructure limitations, and cost barriers profoundly restrict access to HSCT. By assisting local healthcare providers, promoting capacity building, and sharing expertise, DKMS is mitigating disparities in cancer treatment outcomes worldwide. This humanitarian dimension underscores the organization’s commitment not just to scientific advancement but also to social responsibility.

The legacy of John A. Hansen, after whom the research grant is named, continues to inspire. Hansen’s pioneering contributions to hematopoietic stem cell transplantation have left an indelible mark on the field. His work at the Fred Hutchinson Cancer Research Center advanced the safety and efficacy of both blood stem cell and bone marrow transplants, establishing protocols still foundational today. Honoring his memory through this grant propels forward his vision of innovation and improved patient outcomes, encouraging young scientists to build on his seminal discoveries.

In the context of transplant immunology, one particularly vital area of research involves the interplay between donor-derived immune cells and residual host immune systems. Studies funded by the DKMS grant frequently examine immune reconstitution kinetics, chimerism stability, and mechanisms of immune escape utilized by malignant cells post-transplant. These investigations harness high-dimensional immunophenotyping, single-cell sequencing, and bioinformatics to unravel cellular heterogeneity and functional plasticity within the transplant milieu. The goal is to identify biomarkers predictive of relapse or complications, enabling personalized therapeutic interventions.

Furthermore, advancements in cell production under DKMS-supported projects have expanded the frontiers of regenerative medicine and cellular therapeutics. Efforts include optimizing the ex vivo expansion of hematopoietic stem and progenitor cells, improving engraftment potential, and exploring gene-editing technologies for correcting inherited blood disorders prior to transplantation. Such methodologies present profound implications for treating not only cancer but also genetic hematologic diseases, heralding a new era in curative therapies.

Donor selection, once reliant primarily on basic HLA allele matching, now integrates complex genomic data and machine learning algorithms, enhancing compatibility assessments. DKMS’s powerful HLA typing laboratory harnesses next-generation sequencing and bioinformatics pipelines, setting global benchmarks in accuracy and resolution. This precision has a direct clinical impact: refined donor-recipient matching reduces the incidence of acute and chronic GVHD, paving the way for better long-term transplant success and quality of life for patients.

Innovative diagnostic and therapeutic strategies emerging from DKMS-supported research stretch beyond traditional chemotherapy and radiation. They encompass cellular immunotherapies such as CAR T-cell therapy, novel monoclonal antibodies, and immune checkpoint inhibitors adapted for post-transplant settings. These targeted approaches are designed to eradicate minimal residual disease, circumvent resistance mechanisms, and enhance immune surveillance against malignancies. Collectively, they embody the future of precision oncology in the blood cancer domain.

The clinical relevance of this research commitment cannot be overstated. Blood cancer remains a significant global health burden with high morbidity and mortality rates. With more than 1.3 million new cases of leukemia, lymphoma, and myeloma diagnosed annually worldwide, innovations driven by DKMS-supported scientists hold promise to transform therapeutic algorithms, improve survival rates, and reduce treatment-related toxicities. Empowering young investigators with the resources and mentorship to pursue these ambitious goals ensures a continuous influx of novel ideas and accelerates translation from bench to bedside.

At the heart of DKMS’s approach is a comprehensive vision that integrates research, clinical care, donor registry management, and global health equity. This holistic framework fosters a dynamic environment where technological advances intersect with clinical needs and humanitarian missions. By investing in early-career researchers, DKMS is not only nurturing individual scientific talent but also safeguarding the collective future of blood cancer research and patient care worldwide.

In summary, the DKMS John Hansen Research Grant exemplifies a strategic and visionary investment in innovative blood cancer research. With a focus spanning transplant immunology, cell production, donor selection, and novel therapies, it empowers young scientists to pioneer advancements that will redefine the standards of care. Supported by unparalleled infrastructure and a commitment to global impact, DKMS continues to revolutionize the field and offer hope to millions affected by hematologic malignancies.

Subject of Research: Blood cancer treatment, stem cell transplantation, transplant immunology, donor selection, post-transplant complications, novel diagnostic and therapeutic strategies.

Article Title: DKMS John Hansen Research Grant: Accelerating Innovative Blood Cancer Therapies Through Next-Generation Scientific Leadership

News Publication Date: Not specified

Web References: https://professional.dkms.org/research-publications/research-grant

Image Credits: © DKMS (Photo: Nick Heidmann)

Keywords: Stem cell research, Blood cancer, Blood diseases, Cell transplantation, Cell therapies, Immunology, Cell biology, Science careers

At the core of this research lies the human leukocyte antigen (HLA) system, a genomic region renowned for its extraordinary polymorphism and central function in immune recognition. The degree of evolutionary divergence within HLA molecules between donors and recipients emerges as a critical determinant of immune compatibility. Demir, Raynaud, Divard, and colleagues meticulously dissected the landscape of HLA disparity, emphasizing that it is not merely the quantity but the nuanced quality of molecular mismatches that fuel the immune assault against kidney allografts. Their work delineates how evolutionary divergence shapes the antigenic landscape presented to the recipient’s immune system, influencing the propensity for AMR development.

Antibody-mediated rejection remains the most formidable adversary in kidney transplantation, often culminating in irreversible damage and graft loss. Unlike cellular rejection, which involves T lymphocytes, AMR is orchestrated by donor-specific antibodies targeting HLA molecules expressed on the graft endothelium. These antibodies activate complement cascades and recruit effector cells, leading to microvascular injury. Despite advances in immunosuppressive regimens, AMR continues to impose significant clinical burdens. The study probes the heterogeneity of donor-recipient mismatches at a molecular level, revealing that subtle evolutionary distances in HLA genes intricately modulate antibody binding and complement activation dynamics.

The methodology employed by the researchers is a testament to interdisciplinary innovation. By harnessing high-resolution genotyping alongside computational algorithms quantifying evolutionary divergence, the team achieved a granular characterization of donor-recipient HLA disparities. This approach surpasses conventional allele-matching techniques, unveiling cryptic molecular incompatibilities that evade routine compatibility assessments. Such precision promises to refine organ allocation paradigms, optimally pairing donors and recipients to minimize immunological discordance and, consequently, the risk of AMR.

An intriguing aspect illuminated by the study is the differential impact of class I and class II HLA evolutionary divergence on graft outcomes. Class I molecules, integral in presenting endogenous peptides to cytotoxic T cells, exhibit variable evolutionary distances that appear to differentially influence antibody specificity and affinity. Conversely, class II molecules, paramount for the activation of helper T cells and subsequent antibody production, reveal distinct patterns of mismatches correlating with heightened AMR susceptibility. These findings challenge prior assumptions that primarily focused on allele-level mismatch counts, urging a shift toward evolutionary informed compatibility metrics.

Moreover, the intricate interplay between molecular mismatches and the recipient’s immune repertoire emerges as a highlight of this research. The investigators outline that certain epitope configurations, shaped by evolutionary divergence, may either masquerade as self or trigger robust alloimmune responses. This duality underscores the complexity of immune recognition, where structural and biochemical properties of mismatched HLA molecules dictate the immunogenic potential. By decoding these molecular signatures, the study paves the way for predictive models that can forecast AMR risk with unprecedented accuracy.

Clinically, the ramifications of these discoveries are far-reaching. The ability to integrate HLA evolutionary divergence metrics into pre-transplant evaluations could transform risk stratification strategies. Patients at higher immunological risk could benefit from tailored immunosuppression protocols or enhanced surveillance, thereby mitigating adverse outcomes. Additionally, these insights hold promise for the development of novel therapeutics aimed at modulating antibody responses against high-divergence epitopes, potentially curbing the destructive cascade of AMR.

From an evolutionary standpoint, the study offers a fascinating glimpse into how natural selection pressures have sculpted the HLA locus. The observed divergence, while beneficial in pathogen recognition diversity, paradoxically complicates organ transplantation compatibility. This evolutionary trade-off exemplifies the challenges faced in harmonizing the immune system’s protective imperatives with the demands of medical intervention. It also encourages a broader reflection on how evolutionary biology can inform clinical practices in transplantation immunology.

The team’s use of robust statistical modeling and comprehensive cohorts adds considerable weight to their conclusions. By analyzing patient data alongside molecular profiles, they established statistically significant correlations between evolutionary divergence metrics and AMR incidence. These correlations held true across diverse demographic groups, suggesting the universal applicability of their findings. Such rigorous validation reinforces the potential for these metrics to be embraced within the transplant community globally.

Interestingly, the study discerns that not all molecular mismatches bear equal immunological consequences. Certain structural characteristics influenced by evolutionary divergence appear to potentiate stronger antibody responses, while others remain relatively immunologically inert. This nuanced understanding beckons further structural biology studies to delineate the precise atomic interactions driving these differential responses. Such endeavors may unlock targeted interventions that specifically address the most deleterious molecular mismatches.

Furthermore, the researchers underscore the dynamic nature of AMR pathogenesis, influenced by temporal factors and immune memory formation. The interplay between molecular mismatches and the evolving immune landscape post-transplantation introduces layers of complexity in managing graft rejection. The potential for iterative evaluation of HLA divergence and antibody profiles post-transplant could herald a new era of personalized medicine, where real-time immunological assessments inform adaptive therapeutic strategies.

In light of these revelations, future directions abound. The integration of artificial intelligence and machine learning algorithms to predict AMR based on evolutionary divergence data could revolutionize transplant immunology. Additionally, expanding the scope of this research to other organ systems may reveal conserved principles or unique differences pertinent to each transplant context. The translation of these findings into clinical guidelines, however, necessitates collaborative efforts across immunologists, transplant surgeons, and bioinformaticians.

The broader implications transcend transplantation medicine alone. Understanding how HLA evolutionary divergence modulates antibody responses could illuminate fundamental immune processes relevant to autoimmunity, vaccine design, and infectious disease susceptibility. This cross-pollination of insights accentuates the interconnectedness of immunological challenges and the promise of evolutionary-informed science to address them.

In conclusion, the pioneering work by Demir and colleagues intricately maps the contours of HLA evolutionary divergence and its profound impact on antibody-mediated rejection in kidney allografts. Through meticulous molecular and clinical analyses, they reveal the hidden complexity dictating graft fate, offering promising avenues for improved patient outcomes. As the field embraces these insights, the dream of durable kidney transplantation, free from the specter of rejection, steps closer to reality. This study stands as a landmark, inspiring continued exploration at the intersection of evolutionary biology and clinical immunology.

Subject of Research: The impact of human leukocyte antigen (HLA) evolutionary divergence and donor-recipient molecular mismatches on antibody-mediated rejection in kidney transplants.

Article Title: Impact of HLA evolutionary divergence and donor-recipient molecular mismatches on antibody-mediated rejection of kidney allografts.

Article References:
Demir, Z., Raynaud, M., Divard, G. et al. Impact of HLA evolutionary divergence and donor-recipient molecular mismatches on antibody-mediated rejection of kidney allografts. Nat Commun 16, 5692 (2025). https://doi.org/10.1038/s41467-025-60485-y

Image Credits: AI Generated